Novo Holdings
Innovation can end China's healthcare downcycle - AVCJ Forum
Investors in Chinese healthcare are looking for innovators with global competencies to lead an industry recovery following a challenging past 12 months, the AVCJ Private Equity & Venture Forum China 2023 heard.
Astra leads Series D for Indonesia health-tech player Halodoc
Indonesia-based healthcare technology platform Halodoc has completed its Series D round with USD 100m in commitments. It comes more than two years after the company raised USD 80m in Series C funding.
Singapore's Doctor Anywhere raises $38m, makes acquisition
Southeast Asia-focused telehealth platform Doctor Anywhere has closed a second tranche of Series C funding worth USD 38.8m and acquired Singapore-listed Asian Healthcare Specialists (AHS).
ESG: The case for convergence
With ISSB pursuing pre-eminence in sustainability-related financial disclosures and TCFD emerging as a preferred climate framework, investors and investees will have to get more serious about reporting
LPs’ ESG checklists get ever more intricate – AVCJ Forum
LPs want more nuanced emissions measurement from their portfolio managers, the AVCJ ESG Forum heard.
Novo Holdings leads $50m round for India's MedGenome
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a USD 50m investment in MedGenome, an India-based genetic testing business.
Goldman, Sofina lead Series C for China CDMO Zhenge
Goldman Sachs Asset Management and Sofina have led a USD 100m Series C round for Zhenge Biotech, a Shanghai-based contract development and manufacturing organisation (CDMO).
AGIC exits healthcare business Ritedose to Novo Holdings
AGIC Capital, which specializes in cross-border deals along the China-Europe axis, has agreed to sell pharmaceutical manufacturing and packaging business Ritedose Corporation to Novo Holdings.
Deal focus: Singapore's Doctor Anywhere raises $65m Series C
Doctor Anywhere’s omnichannel approach to digitizing Southeast Asian healthcare is luring investors with eyes on the pandemic’s most logical trend. Preserving a first-mover advantage is the challenge
Vivo, Novo back Singapore's Esco Lifesciences
Vivo Capital and Novo Holdings have led a $200 million Series A round for Esco Lifesciences, a Singapore-based manufacturer of biopharma lab equipment and medical devices.
Deal focus: Novo spreads its wings in Southeast Asia
In Hummingbird Bioscience and Halodoc, Novo Holdings believes it has backed a potential global leader in hard-to-drug cancer and a likely domestic champion in telemedicine and disease management
Singapore biotech start-up closes $125m Series C
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has led a $125 million Series C round for Hummingbird Bioscience, a Singapore and US-based drug developer.
Novo Holdings joins $80m Series C for Indonesia's Halodoc
Novo Holdings, which manages the wealth of Denmark’s Novo Nordisk Foundation, has made its first investment in an Asian healthcare company by participating in an $80 million Series C round for Indonesia healthcare technology provider Halodoc.
Novo Tellus backs Singapore semiconductor industry supplier
Novo Tellus Capital Partners has invested S$23.6 million ($17.7 million) in Grand Venture Technology, a Singapore-listed provider of testing, assembly, and engineering services for semiconductor manufacturing.
Q&A: Novo Holdings' Amit Kakar
Having spent the past three years on healthcare buy-and-build platform Everlife Asia, Amit Kakar’s is joining life sciences investor Novo Holdings as regional head. He explains why now is the time to bet big on Asia